Download Files:
Products Details
Product Description
– SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs[1]. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
Web ID
– HY-153962
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C78H95N9O20
References
– [1]Govindan Serengulam V, et al. Antibody-SN-38 immunoconjugates with a CL2A linker. Patent. US20140227180.
CAS Number
– 1373170-36-5
Molecular Weight
– 1478.64
SMILES
– O=C1[C@](OC(OCC2=CC=C(NC([C@@H](NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])=O)=O)CCCCNC(C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=C(OC)C=C5)=O)C=C2)=O)(CC)C6=C(CO1)C(N7CC8=C(CC)C9=CC(O)=CC=C9N=C8C7=C6)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Drug-Linker Conjugates for ADC
Pathway
– Antibody-drug Conjugate/ADC Related
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
